<--- Back to Details
First PageDocument Content
Clinical medicine / Medicine / Antineoplastic drugs / Breakthrough therapy / Pharmacology / Bristol-Myers Squibb / Monoclonal antibodies / Immune system / Programmed cell death protein 1 / Nivolumab / Pharmac / Pembrolizumab
Date: 2016-05-25 01:37:50
Clinical medicine
Medicine
Antineoplastic drugs
Breakthrough therapy
Pharmacology
Bristol-Myers Squibb
Monoclonal antibodies
Immune system
Programmed cell death protein 1
Nivolumab
Pharmac
Pembrolizumab

24 MayDanae Staples-Moon Therapeutic Group Manager PHARMAC PO Box

Add to Reading List

Source URL: www.nzma.org.nz

Download Document from Source Website

File Size: 204,92 KB

Share Document on Facebook

Similar Documents

A Day in Life at BMS Welcome to A Day in Life at BMS where you will meet leaders from our R&D organization and learn more about research and development at Bristol-Myers Squibb, as well as network with our scientists. To

A Day in Life at BMS Welcome to A Day in Life at BMS where you will meet leaders from our R&D organization and learn more about research and development at Bristol-Myers Squibb, as well as network with our scientists. To

DocID: 1vrK6 - View Document

NoIN THE Supreme Court of the United States BRISTOL-MYERS SQUIBB COMPANY, PETITIONER,

NoIN THE Supreme Court of the United States BRISTOL-MYERS SQUIBB COMPANY, PETITIONER,

DocID: 1tuCc - View Document

Bristol-Myers Squibb Co. v. Superior Court of Cal., San Francisco Cty)

Bristol-Myers Squibb Co. v. Superior Court of Cal., San Francisco Cty)

DocID: 1tut4 - View Document

September 2003 USA Bristol-Myers Squibb Medical Imaging

September 2003 USA Bristol-Myers Squibb Medical Imaging

DocID: 1sKnx - View Document

May 2003 Bristol-Myers Squibb Medical Imaging 331 Treble Cove Road N. Billerica, Massachusetts 01862

May 2003 Bristol-Myers Squibb Medical Imaging 331 Treble Cove Road N. Billerica, Massachusetts 01862

DocID: 1sC8T - View Document